
Gradient Medical Inc Profile last edited on: 9/29/2022
CAGE: 8PTM2
UEI: HPZ7FS9MF8J1
Business Identifier: Novel interventional oncology therapies: pulsed electric field therapies Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 13
County: Wake
Congr. District: 13
County: Wake
Public Profile
Gradient Medical develops interventional oncology solutions and services with a focus on bringing ACE therapy to clinics. The firm's ACE (Algorithmically Controlled Electroporation) therapy delivers electrical pulses that target cancer cells and disrupt biological functions while offering real time sensing to give clinicians control over the treatment zone and maximize therapeutic effectiveness and minimize treatment times. This solution enables clinicians to treat inoperable tumors near critical structures, treating the precise size and shape needed. Algorithmically Controlled Electroporation offers a closed loop temperature regulated pulsed electric field cancer ablation through the creation of a 3D tumor model that enables evaluation of specific treatment parameters at physiological temperatures that is not possible with other systems such as open-loop.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2022 | 1 | NIH | $259,549 | |
Project Title: Feasibility of a Multi-Phase Algorithmic Non-Thermal Ablation Technology for the Treatment of Inoperable Tumors | ||||
2021 | 1 | NIH | $251,914 | |
Project Title: Feasibility of INSPIRE Technology to Enhance CRISPR Mediated Genome Editors in Vivo | ||||
2021 | 1 | NSF | $255,930 | |
Project Title: Pulsed Electric Field Mediated Intradermal Vaccine Delivery (COVID-19) |
Key People / Management
Michael Sano -- Founder and CEO
Matthew DeWitt -- Director of Research & Development
Matthew DeWitt -- Director of Research & Development